Metastasis-directed radiation therapy plus hormone therapy improves PFS for men with advanced prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers from MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented Oct. 25 at the 2022 American Society for Radiation Oncology Annual Meeting.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents